Andrew JD - Verve Therapeutics COO President
| VERV Stock | USD 6.01 0.25 3.99% |
President
Andrew JD is COO President of Verve Therapeutics
| Age | 57 |
| Address | 201 Brookline Avenue, Cambridge, MA, United States, 02215 |
| Phone | 617 603 0070 |
| Web | https://www.vervetx.com |
Verve Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1948) % which means that it has lost $0.1948 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3478) %, meaning that it created substantial loss on money invested by shareholders. Verve Therapeutics' management efficiency ratios could be used to measure how well Verve Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. At this time, Verve Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 120.5 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 1.4 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Tracey McCain | Blueprint Medicines Corp | 50 | |
| Kelly Blackburn | aTyr Pharma | 50 | |
| Julie Rubinstein | Adaptive Biotechnologies Corp | 52 | |
| Willis | Adaptive Biotechnologies Corp | N/A | |
| Hyam MD | Century Therapeutics | 66 | |
| Laura SeppLorenzino | Intellia Therapeutics | 63 | |
| Andrew Cubitt | aTyr Pharma | 51 | |
| Melissa Ashlock | aTyr Pharma | 66 | |
| John McKew | aTyr Pharma | 50 | |
| Frank Williams | Adaptive Biotechnologies Corp | 46 | |
| Kala Subramanian | Crispr Therapeutics AG | 49 | |
| Holly Chrzanowski | aTyr Pharma | 48 | |
| David King | aTyr Pharma | 65 | |
| Andrew Schiermeier | Intellia Therapeutics | 48 | |
| Lindsey Trickett | Intellia Therapeutics | N/A | |
| Graeme Bell | Intellia Therapeutics | 50 | |
| Megan Menner | Crispr Therapeutics AG | N/A | |
| Glenn Goddard | Intellia Therapeutics | 47 | |
| Fouad MD | Blueprint Medicines Corp | 55 | |
| John Leonard | Intellia Therapeutics | 60 | |
| Nancy Hill | Adaptive Biotechnologies Corp | N/A | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.19 |
Verve Therapeutics Leadership Team
Elected by the shareholders, the Verve Therapeutics' board of directors comprises two types of representatives: Verve Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Verve. The board's role is to monitor Verve Therapeutics' management team and ensure that shareholders' interests are well served. Verve Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Verve Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joan MBA, Chief Officer | ||
| FACC MD, CoFounder | ||
| Anthony MD, CoFounder Member | ||
| Allison Dorval, CFO Officer | ||
| Andrew JD, COO President | ||
| Andrew MD, Chief Officer | ||
| Sekar MD, CEO CoFounder | ||
| Margaret Beaudoin, VP Fin | ||
| Issi MBA, CoFounder Advisor | ||
| MD MPH, CoFounder Advisor | ||
| Burt MD, CoFounder Board |
Verve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Verve Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (10.49) % | ||||
| Current Valuation | (25.59 M) | ||||
| Shares Outstanding | 83.92 M | ||||
| Shares Owned By Insiders | 7.62 % | ||||
| Shares Owned By Institutions | 86.89 % | ||||
| Number Of Shares Shorted | 15.69 M | ||||
| Price To Earning | 5.45 X | ||||
| Price To Book | 1.06 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verve Therapeutics is a strong investment it is important to analyze Verve Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Verve Therapeutics' future performance. For an informed investment choice regarding Verve Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verve Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Verve Stock analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Verve Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verve Therapeutics. If investors know Verve will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verve Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.183 | Quarterly Revenue Growth 4.083 | Return On Assets (0.19) | Return On Equity (0.35) |
The market value of Verve Therapeutics is measured differently than its book value, which is the value of Verve that is recorded on the company's balance sheet. Investors also form their own opinion of Verve Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Verve Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verve Therapeutics' market value can be influenced by many factors that don't directly affect Verve Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verve Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verve Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verve Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.